View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
December 16, 2019updated 12 Jul 2022 11:59am

China is the rising star in clinical trials

China has the potential to recruit an adequate number of participants for clinical trials of any size.

By GlobalData Healthcare

China, the world’s largest country by population (20% of the world’s population), is an ideal location to run a clinical trial. With over one billion individuals and growing, China has the potential to recruit an adequate number of participants for clinical trials of any size. The number of clinical trials is also increasing as the population increases.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

This can be seen in an analysis of the current clinical trials space for China using the Clinical Trials Database of GlobalData’s Pharma Intelligence Center.

When looking at clinical trials in China in the database, the percentage of trials relative to global clinical trials has increased steadily over the years. Since 2000, it has risen from 1% of the global total to 21% in 2018. This can be seen in Figure 1. By sponsor type, industry-sponsored clinical trials in China are outnumbered by non-industry sponsored trials by about 40%: industry-sponsored clinical trials make up 31%, while non-industry sponsored trials are 69% (Figure 2).

Lastly, non-industry sponsored clinical trials outnumbered industry-sponsored trials every year except 2000 and 2001. In 2000, they were levelled at 50% while in 2001, industry-sponsored trials were more numerous by 4% (Figure 3).

 

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena